




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 213/53, A61K 31/44	A1	(11) International Publication Number: WO 96/00215 (43) International Publication Date: 4 January 1996 (04.01.96)
<p>(21) International Application Number: PCT/GB95/01474</p> <p>(22) International Filing Date: 23 June 1995 (23.06.95)</p> <p>(30) Priority Data: 9412672.9 23 June 1994 (23.06.94) GB</p> <p>(71) Applicant: CELLTECH THERAPEUTICS LIMITED [GB/GB]; 216 Bath Road, Slough, Berkshire SL1 4EN (GB).</p> <p>(72) Inventors: HEAD, John, Clifford; Flat 2A, 8 Claremont Road, Windsor, Berkshire SL4 3AX (GB). WARRELOW, Graham, John; Oakside, 4 Wieland Road, Northwood, Middlesex HA6 3QU (GB). ALEXANDER, Rikki, Peter; 14 Carrington Road, High Wycombe, Bucks HP12 3HY (GB).</p> <p>(74) Agent: SKAILES, Humphrey, John; Frank B. Dehn & Co., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB).</p>		<p>(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: SUBSTITUTED OXIME DERIVATIVES USEFUL AS PDE IV INHIBITORS</p>		
<p>(57) Abstract</p> <p>Compounds of formula (1) are described wherein =W- is (1) =C(Y)- where Y is a halogen atom, or an alkyl or -XR^a group where X is -O-, -S(O)_m [where m is zero or an integer of value (1) or (2)], or -N(R^b)- [wherein R^b is a hydrogen atom or an optionally substituted alkyl group] and R^a is a hydrogen atom or an optionally substituted alkyl group or, (2) =N-; L is a -XR, [where R is an optionally substituted alkyl, alkenyl, cycloalkyl or cyloalkenyl group], -C(R⁵)-C(R¹)(R²) or [-CH(R⁵)]_nCH(R¹)(R²) group where R⁵ is a hydrogen or a fluorine atom or a methyl group, and R¹ and R², which may be the same or different, is each a hydrogen or fluorine atom or an optionally substituted alkyl, alkenyl, alkynyl, alkoxy, alkylthio, -CO₂R⁶, [where R⁶ is a hydrogen atom or an optionally substituted alkyl, aralkyl, or aryl group], -CONR⁷R⁸ [where R⁷ and R⁸, which may be the same or different are as defined for R⁶], -CSNR⁷R⁸, -CN or -NO₂ group, or R¹ and R² together with the C atom to which they are attached are linked to form an optionally substituted cycloalkyl or cycloalkenyl group and n is zero or the integer (1); Ar is a group -(CH₂)_n-Z-Ar' where Ar' is an optionally substituted monocyclic or bicyclic heteroaryl group and Z is a bond, an atom -O-, or -S- or a group -N(R^b)- and n is zero or the integer 1, 2, 3 or 4; R³ is a hydrogen atom, or an optionally substituted alkyl, alkenyl, alkynyl, -C(O)R⁴ (where R⁴ is an amino, alkylamino, arylamino, alkoxy, aryloxy or an optionally substituted alkyl group) or -C(S)R⁴ group; and the salts, solvates, hydrates, prodrugs and N-oxides thereof. Compounds according to the invention are phosphodiesterase type IV inhibitors and are useful in the prophylaxis and treatment of disease such as asthma where an unwanted inflammatory response or muscular spasm is present.</p> <div style="text-align: center;">  </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

SUBSTITUTED OXIME DERIVATIVES USEFUL AS PDE IV INHIBITORS

- 5 This invention relates to a novel series of substituted oxime derivatives, to processes for their preparation, to pharmaceutical compositions containing them, and to their use in medicine.

10 Many hormones and neurotransmitters modulate tissue function by elevating intra-cellular levels of adenosine 3', 5'-cyclic monophosphate (cAMP). The cellular levels of cAMP are regulated by mechanisms which control synthesis and breakdown. The synthesis of cAMP is controlled by adenylyl cyclase which may be directly activated by agents such as forskolin or indirectly activated by the binding of specific agonists to cell surface
15 receptors which are coupled to adenylyl cyclase. The breakdown of cAMP is controlled by a family of phosphodiesterase (PDE) isoenzymes, which also control the breakdown of guanosine 3',5'-cyclic monophosphate (cGMP). To date, seven members of the family have been described (PDE I-VII) the distribution of which varies from tissue to tissue. This
20 suggests that specific inhibitors of PDE isoenzymes could achieve differential elevation of cAMP in different tissues, [for reviews of PDE distribution, structure, function and regulation, see Beavo & Reifsnyder (1990) TIPS, 11: 150-155 and Nicholson et al (1991) TIPS, 12: 19-27].

- 25 There is clear evidence that elevation of cAMP in inflammatory leukocytes leads to inhibition of their activation. Furthermore, elevation of cAMP in airway smooth muscle has a spasmolytic effect. In these tissues, PDE IV plays a major role in the hydrolysis of cAMP. It can be expected, therefore, that selective inhibitors of PDE IV would have therapeutic
30 effects in inflammatory diseases such as asthma, by achieving both anti-inflammatory and bronchodilator effects.


The design of PDE IV inhibitors has met with limited success to date, in that many of the potential PDE IV inhibitors which have been synthesised
35 have lacked potency and/or have been capable of inhibiting more than one type of PDE isoenzyme in a non-selective manner. Lack of a selective

action has been a particular problem given the widespread role of cAMP *in vivo* and what is needed are potent selective PDE IV inhibitors with an inhibitory action against PDE IV and little or no action against other PDE isoenzymes.

5

We have now found a novel series of tri-substituted phenyl derivatives, members of which are potent inhibitors of PDE IV at concentrations at which they have little or no inhibitory action on other PDE isoenzymes. These compounds inhibit the human recombinant PDE IV enzyme and
10 also elevate cAMP in isolated leukocytes. The compounds of the invention are therefore of use in medicine, especially in the prophylaxis and treatment of asthma.

Thus according to one aspect of the invention, we provide a compound of
15 formula (1)



wherein

- 20 =W- is (1) =C(Y)- where Y is a halogen atom, or an alkyl or -XR^a group where X is -O-, -S(O)_m- [where m is zero or an integer of value 1 or 2], or -N(R^b)- [where R^b is a hydrogen atom or an optionally substituted alkyl group] and R^a is a hydrogen atom or an optionally substituted alkyl group or, (2) =N-;
- 25 L is a -XR, [where R is an optionally substituted alkyl, alkenyl, cycloalkyl or cyloalkenyl group], -C(R⁵)=C(R¹)(R²) or [-CH(R⁵)]_nCH(R¹)(R²) group where R⁵ is a hydrogen or a fluorine atom or a methyl group, and R¹ and R², which may be the same or different, is each a hydrogen or fluorine atom or an optionally substituted alkyl, alkenyl, alkynyl, alkoxy, alkylthio,
- 30 -CO₂R⁶, [where R⁶ is a hydrogen atom or an optionally substituted alkyl, aralkyl, or aryl group], -CONR⁷R⁸ [where R⁷ and R⁸, which may be the same or different are as defined for R⁶], -CSNR⁷R⁸, -CN or -NO₂ group, or R¹ and R² together with the C atom to which they are attached are linked

to form an optionally substituted cycloalkyl or cycloalkenyl group and n is zero or the integer 1;

Ar is a group $-(CH_2)_n-Z-Ar'$ where Ar' is an optionally substituted monocyclic or bicyclic heteroaryl group and Z is a bond, an atom -O-, or
5 -S- or a group $-N(R^b)-$ and n is zero or the integer 1, 2, 3 or 4;

R^3 is a hydrogen atom, or an optionally substituted alkyl, alkenyl, alkynyl, $-C(O)R^4$ (where R^4 is an amino, alkylamino, arylamino, aryl, aryloxy, alkoxy or an optionally substituted alkyl group) or $-C(S)R^4$ group; and the salts, solvates, hydrates, prodrugs, and N-oxides thereof.

10

Compounds of formula (1) may exist as geometric isomers and the invention is to be understood to extend to all such isomers and mixtures thereof.

15 In the compounds of formula (1), when $=W-$ is $=C(Y)-$ and Y is a halogen atom Y may be for example a fluorine, chlorine, bromine or iodine atom.

When W in the compounds of formula (1) is a group $=C(Y)-$ and Y is $-XR^a$, R^a may be, for example, a hydrogen atom or an optionally substituted
20 straight or branched alkyl group, for example, an optionally substituted C_{1-6} alkyl group, such as a methyl, ethyl, n-propyl or i-propyl group. Optional substituents which may be present on R^a groups include one or more halogen atoms, e.g. fluorine, or chlorine atoms. Particular R^a groups include for example $-CH_2F$, $-CH_2Cl$, $-CHF_2$, $-CHCl_2$, $-CF_3$ or $-CCl_3$ groups.

25

When $=W-$ in the compounds of formula (1) is a group $=C(Y)-$ where $-Y$ is $-N(R^b)$, $=W-$ may be a $=C(NH_2)-$, $=C(NHCH_3)-$ or $=C(NHC_2H_5)-$ group.

In compounds of formula (1), X may be an oxygen or a sulphur atom, or a
30 group $-S(O)-$, $-S(O)_2-$, $-NH-$ or C_{1-6} alkylamino, for example a C_{1-3} alkylamino, e.g. methylamino $[-N(CH_3)-]$ or ethylamino $[-N(C_2H_5)-]$ group.

Alkyl groups represented by Y, R, R^1 , R^2 , or R^b in the compounds of formula (1) include optionally substituted straight or branched C_{1-6} alkyl
35 groups optionally interrupted by one or more X atoms or groups. Particular examples include C_{1-3} alkyl groups such as methyl or ethyl

groups. Optional substituents on these groups include one, two or three substituents selected from halogen atoms, e.g. fluorine, chlorine, bromine or iodine atoms, or hydroxyl or C₁₋₆ alkoxy e.g. C₁₋₃ alkoxy such as methoxy or ethoxy or -CO₂R⁶, -CONR⁷R⁸, -CSNR⁷R⁸ or -CN groups.

5

Alkenyl groups represented by R, R¹ or R² in the compounds of formula (1) include optionally substituted straight or branched C₂₋₆alkenyl groups optionally interrupted by one or more X atoms or groups. Particular examples include ethenyl, propen-1-yl and 2-methylpropen-1-yl groups.

10 Optional substituents include those described above in relation to alkyl groups represented by the groups R¹ or R².

15 Alkynyl groups represented by R¹ or R² in compounds of formula (1) include optionally substituted straight or branched C₂₋₆alkynyl groups optionally interrupted by one or more X atoms or groups. Particular examples include ethynyl and propyn-1-yl groups. Optional substituents include those described above in relation to alkyl groups represented by the groups R¹ or R².

20 When R¹ or R² in compounds of formula (1) is an alkoxy or alkylthio group it may be for example an optionally substituted straight or branched C₁₋₆alkoxy or C₁₋₆alkylthio group optionally interrupted by one or more X atoms or groups. Particular examples include C₁₋₃alkoxy, e.g. methoxy or ethoxy, or C₁₋₃alkylthio e.g. methylthio or ethylthio groups. Optional
25 substituents include those described above in relation to alkyl groups represented by the groups R¹ or R².

30 When R¹ and R² together with the carbon atom to which they are attached in the compounds of formula (1) are linked to form a cycloalkyl or cycloalkenyl group, the group may be for example a C₃₋₈cycloalkyl group such as a cyclobutyl, cyclopentyl or cyclohexyl group or a C₃₋₈ cycloalkenyl group containing for example one or two double bonds such as a 2-cyclobuten-1-yl, 2-cyclopenten-1-yl, 3-cyclopenten-1-yl, 2,4-cyclopentadien-1-yl, 2-cyclohexen-1-yl, 3-cyclohexen-1-yl, 2,4-cyclohexadien-1-yl or 3,5-cyclohexadien-1-yl group, each cycloalkyl or
35 cycloalkenyl group being optionally substituted by one, two or three

substituents selected from halogen atoms, e.g. fluorine, chlorine, bromine or iodine atoms, straight or branched C₁₋₆alkyl e.g. C₁₋₃alkyl such as methyl or ethyl, hydroxyl or C₁₋₆alkoxy e.g. C₁₋₃alkoxy such as methoxy or ethoxy groups.

5

When R in the compounds of formula (1) is an optionally substituted cycloalkyl or cycloalkenyl group it may be for example a C₃₋₈cycloalkyl group such as a cyclobutyl, cyclopentyl or cyclohexyl group or a C₃₋₈ cycloalkenyl group containing for example one or two double bonds such as a 2-cyclobuten-1-yl, 2-cyclopenten-1-yl, 3-cyclopenten-1-yl, 2,4-cyclopentadien-1-yl, 2-cyclohexen-1-yl, 3-cyclohexen-1-yl, 2,4-cyclohexadien-1-yl or 3,5-cyclohexadien-1-yl group, each cycloalkyl or cycloalkenyl group being optionally substituted by one, two or three substituents selected from halogen atoms, e.g. fluorine, chlorine, bromine or iodine atoms, straight or branched C₁₋₆alkyl e.g. C₁₋₃alkyl such as methyl or ethyl, hydroxyl or C₁₋₆alkoxy e.g. C₁₋₃alkoxy such as methoxy or ethoxy groups.

Alkyl groups represented by R³ or R⁴ in compounds of formula (1) include optionally substituted straight or branched C₁₋₆ alkyl groups, e.g. C₁₋₃ alkyl groups such as methyl, ethyl, n-propyl or i-propyl groups. Optional substituents which may be present on these groups include one or more halogen atoms, e.g. fluorine, chlorine, bromine or iodine atoms, or hydroxyl, C₁₋₆alkoxy e.g. C₁₋₃alkoxy such as methoxy or ethoxy groups, Ar' where Ar' is as described above, or aryl e.g. optionally substituted C₆₋₁₂ aryl, e.g. phenyl groups.

Alkenyl or alkynyl groups represented by R³ in compounds of formula (1) include C₂₋₆ alkenyl or C₂₋₆ alkynyl groups as described previously for R¹ groups. Such groups may be substituted, for example by one or more of the substituents listed above for alkyl groups represented by R³.

Alkylamino groups represented by the group R⁴ in compounds of formula (1) include optionally substituted straight or branched C₁₋₆alkylamino groups such as methylamino, ethylamino or propylamino groups. Optional

substituents which may be present include those described above in connection with alkyl groups represented by the group R⁴.

5 When R⁴ is an arylamino group it may be for example a -NHA^r group where A^r is an optionally substituted C₆₋₁₂aryl group, e.g. an optionally substituted phenyl group. Optional substituents include R⁹ substituents described below.

10 Alkoxy groups represented by R⁴ include optionally substituted straight or branched C₁₋₆alkoxy, e.g. methoxy, ethoxy or propoxy groups. Optional substituents which may be present include those described above in connection with alkyl groups represented by the group R⁴.

15 Aryl groups represented by R⁴ include -A^r groups [where A^r is as just defined], for example optionally substituted phenyl groups.

20 When R³ in compounds of formula (1) is a -COR⁴ or CSR⁴ group, it may be for example a -CONH₂, -CONR⁷R⁸, [where R⁷ and R⁸ are as described below], -CONHR⁸, -CSNH₂, -CSNR⁷R⁸, -CSNHR⁸, -COR⁷, -CSR⁷, -C(O)OR⁷, or -C(S)OR⁷ group.

25 When R¹ or R² is a -CO₂R⁶, -CONR⁷R⁸ or CSNR⁷R⁸ group it may be for example a -CO₂H, -CONH₂ or -CSNH₂ group or a group -CO₂R⁶, -CONR⁷R⁸, -CSNR⁷R⁸, -CONHR⁸ or -CSNHR⁸ where R⁶, R⁷ and R⁸ where present is a C₁₋₃alkyl group such as methyl or ethyl group, a C₆₋₁₂aryl group, for example an optionally substituted phenyl, or a 1- or 2-naphthyl group, or a C₆₋₁₂aryl C₁₋₃alkyl group such as an optionally substituted benzyl or phenethyl group. Optional substituents which may be present on these aryl groups include R⁹ substituents discussed below in relation to the group Ar.

35 Monocyclic or bicyclic heteroaryl groups represented by A^r include for example a C₁₋₉ optionally substituted heteroaryl group containing for example one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms. Monocyclic heteroaryl groups include for example five- or six-membered heteroaryl groups containing one, two,

three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms. Bicyclic heteroaryl groups include for example nine- or ten-membered heteroaryl groups containing one, two or more heteroatoms selected from oxygen, sulphur or nitrogen atoms.

5

Examples of heteroaryl groups represented by Ar' include pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 10 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, benzofuryl, isobenzofuryl, benzothienyl, isobenzothienyl, indolyl, isoindolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, quinazolinyl, naphthyridinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolinyl, isoquinolinyl, tetrazolyl, 5,6,7,8-tetrahydroquinolinyl and 5,6,7,8-tetrahydroisoquinolinyl. 15 Example of bicyclic heteroaryl groups include quinolinyl or isoquinolinyl groups.

The heteroaryl group represented by Ar' may be attached to the remainder of the molecule of formula (1) through any ring carbon or heteroatom as appropriate. Thus, for example, when the group Ar' is a pyridyl group it 20 may be a 2-pyridyl, 3-pyridyl or 4-pyridyl group. When it is a thienyl group it may be a 2-thienyl or 3-thienyl group, and, similarly, when it is a furyl group it may be a 2-furyl or 3-furyl group. In another example, when the group Ar' is a quinolinyl group it may be a 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolinyl and when it is an isoquinolinyl, it may be a 1-, 3-, 4-, 5-, 6-, 7- or 8- isoquinolinyl group. 25

When in compounds of formula (1) the Ar' group is a nitrogen-containing heterocycle it may be possible to form quaternary salts, for example N-alkyl quaternary salts and the invention is to be understood to extend to 30 such salts. Thus for example when the group Ar' is a pyridyl group, pyridinium salts may be formed, for example N-alkylpyridinium salts such as N-methylpyridinium.

35 The heteroaryl groups represented by Ar' in compounds of formula (1) or aryl substituents present on R³ groups may each optionally be substituted

by one, two, three or more substituents $[R^9]$. The substituent R^9 may be selected from an atom or group R^{10} or $-Alk^2(R^{10})_m$ wherein R^{10} is a halogen atom, or an amino ($-NH_2$), substituted amino, nitro, cyano, hydroxyl ($-OH$), substituted hydroxyl, cycloalkyl, cycloalkoxy, formyl $[HC(O)-]$, carboxyl ($-CO_2H$), esterified carboxyl, thiol ($-SH$), substituted thiol, $-Ar'$, $-Ar$ (where Ar is an aryl group), $-XAr'$, $-XAr$, $-C(O)Alk^2$, $-SO_3H$, $-SO_2Alk^2$, $-SO_2NH_2$, $-SO_2NHAik^2$, $-SO_2N[Alk^2]_2$, $-SO_2NHA_r$, $-SO_2N(Alk^2)Ar$, $CONH_2$, $-CONHAik^2$, $-CON[Alk^2]_2$, $-CONHA_r$, $-CON(Alk^2)Ar$, $-NH SO_2H$, $-NAlk^2SO_2H$, $-NH SO_2Alk^2$, $-N[SO_2Alk^2]_2$, $-NH SO_2NH_2$, $-NAlk^2SO_2NH_2$, $-NH SO_2NHAik^2$, $-NAlk^2SO_2NHAik^2$, $-NH SO_2N[Alk^2]_2$, $-NAlk^2SO_2N[Alk^2]_2$, $-NAlk^2SO_2NHAik^2$, $-NH SO_2NHA_r$, $-NAlk^2SO_2NHA_r$, $-NAlk^2SO_2NAlk^2Ar$, $-NH SO_2NAlk^2Ar$, $-NHC(O)H$, $-NHC(O)Alk^2$, $-NAlk^2C(O)H$, $-NAlk^2C(O)Alk^2$, $-N[C(O)Alk^2]_2$, $-NHC(O)OH$, $-NHC(O)OAlk^2$, $-NAlk^2C(O)OH$, $-NAlk^2C(O)OAlk^2$, $-N[C(O)H]SO_2H$, $-N[C(O)Alk^2]SO_2H$, $-N[C(O)H]SO_2Alk^2$, $N[C(O)Alk^2]SO_2Alk^2$, $-C(S)H$, $C(S)Alk^2$, $-CSNH_2$, $-CSNHAik^2$, $-CSN[Alk^2]_2$, $-CSNHA_r$, $-CSN(Alk^2)Ar$, $-NHC(S)Alk^2$, $-NAlk^2C(S)Alk^2$, $-N[C(S)Alk^2]SO_2H$, $-N[C(S)Alk^2]SO_2Alk^2$, $-NHCONH_2$, $-NHCONH(Alk^2)$, $-NHCON[Alk^2]_2$, $-NAlk^2CONH_2$, $-NAlk^2CONH(Alk^2)$, $-NAlk^2CON[Alk^2]_2$, $-NHCSNH_2$, $-NHCSNH(Alk^2)$, $-NHCSN[Alk^2]_2$, $-NAlk^2CSNH_2$, $-NAlk^2CSNH(Alk^2)$, or $-NAlk^2CSN[Alk^2]_2$ group, Alk^2 is an optionally substituted straight or branched C_{1-6} alkylene, C_{2-6} alkenylene, or C_{2-6} alkynylene chain optionally interrupted by one, two, or three $-O-$, or $-S-$ atoms or $-S(O)_p-$, [where p is an integer 1 or 2] or $-N(R^b)-$ groups; and m is zero or an integer 1, 2 or 3.

When in the group $-Alk^2(R^{10})_m$ m is an integer 1, 2 or 3, it is to be understood that the substituent or substituents R^{10} may be present on any suitable carbon atom in $-Alk^2$. Where more than one R^{10} substituent is present these may be the same or different and may be present on the same or different carbon atom in Alk^2 . Clearly, when m is zero and no substituent R^{10} is present or when Alk^2 forms part of a group such as $-SO_2Alk^2$ the alkylene, alkenylene or alkynylene chain represented by Alk^2 becomes an alkyl, alkenyl or alkynyl group.

When R^{10} is a substituted amino group it may be a group $-NH[Alk^2(R^{10a})_m]$ [where Alk^2 and m are as defined above and R^{10a} is as defined above for

R^{10} but is not a substituted amino, a substituted hydroxyl or a substituted thiol group] or a group $-N[Alk^2(R^{10a})_m]_2$ wherein each $-Alk^2(R^{10a})_m$ group is the same or different.

- 5 When R^{10} is a halogen atom it may be for example a fluorine, chlorine, bromine, or iodine atom.

When R^{10} is a cycloalkoxy group it may be for example a C_{5-7} cycloalkoxy group such as a cyclopentyloxy or cyclohexyloxy group.

10

When R^{10} is a substituted hydroxyl or substituted thiol group it may be a group $-OAlk^2(R^{10a})_m$ or $-SAlk^2(R^{10a})_m$ respectively, where Alk^2 , R^{10a} and m are as just defined.

- 15 Esterified carboxyl groups represented by the group R^{10} include groups of formula $-CO_2Alk^3$ wherein Alk^3 is a straight or branched, optionally substituted C_{1-8} alkyl group such as a methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl or t-butyl group; a C_{6-12} aryl C_{1-8} alkyl group such as an optionally substituted benzyl, phenylethyl, phenylpropyl, 1-naphthylmethyl
- 20 or 2-naphthylmethyl group; a C_{6-12} aryl group such as an optionally substituted phenyl, 1-naphthyl or 2-naphthyl group; a C_{6-12} aryloxy C_{1-8} alkyl group such as an optionally substituted phenyloxymethyl, phenyloxyethyl, 1-naphthyloxymethyl, or 2-naphthyloxymethyl group; an optionally substituted C_{1-8} alkanoyloxy C_{1-8} alkyl group, such as a pivaloyloxymethyl,
- 25 propionyloxyethyl or propionyloxypropyl group; or a C_{6-12} aroyloxy C_{1-8} alkyl group such as an optionally substituted benzoyloxyethyl or benzoyloxypropyl group. Optional substituents present on the Alk^3 group include R^9 substituents described above.

- 30 Particular examples of the chain Alk^2 when present in compounds of formula (1) include methylene, ethylene, n-propylene, i-propylene, n-butylene, i-butylene, s-butylene, t-butylene, ethenylene, 2-propenylene, 2-butenylene, 3-butenylene, ethynylene, 2-propynylene, 2-butylnylene or 3-butylnylene chain, optionally interrupted by one, two, or three -O- or -S-,
- 35 atoms or -S(O)-, -S(O)₂- or -N(R^b)- groups.

Particularly useful atoms or groups represented by R⁹ include fluorine, chlorine, bromine or iodine atoms, or C₁₋₆alkyl, e.g. methyl or ethyl, C₁₋₆alkylamino, e.g. methylamino or ethylamino, C₁₋₆ hydroxyalkyl, e.g. hydroxymethyl or hydroxyethyl, C₁₋₆alkylthiol e.g. methylthiol or ethylthiol,

5 C₁₋₆alkoxy, e.g. methoxy or ethoxy, C₅₋₇ cycloalkyl, e.g. cyclopentyl, C₅₋₇ cycloalkoxy, e.g. cyclopentyloxy, haloC₁₋₆alkyl, e.g. trifluoromethyl, C₁₋₆alkylamino, e.g. methylamino or ethylamino, amino (-NH₂), aminoC₁₋₆alkyl, e.g. aminomethyl or aminoethyl, C₁₋₆dialkylamino, e.g. dimethylamino or diethylamino, nitro, cyano, hydroxyl (-OH), formyl [HC(O)-], carboxyl

10 (-CO₂H), -CO₂Alk³ [where Alk³ is as defined above], C₁₋₆alkanoyl e.g. acetyl, C₁₋₆thiocarbonyl e.g. thioacetyl, thiol (-SH), thio C₁₋₆alkyl, e.g. thiomethyl or thioethyl, C₆₋₁₂aryl, e.g. phenyl, C₆₋₁₂aryloxy, e.g. phenoxy, C₆₋₁₂aralkyl, e.g. benzyl, C₆₋₁₂aralkoxy e.g. benzyloxy, sulphonyl (-SO₃H), C₁₋₆alkylsulphonyl, e.g. methylsulphonyl, aminosulphonyl (-SO₂NH₂),

15 C₁₋₆alkylaminosulphonyl, e.g. methylaminosulphonyl or ethylaminosulphonyl, C₁₋₆dialkylaminosulphonyl, e.g. dimethylaminosulphonyl or diethylaminosulphonyl, phenylaminosulphonyl, carboxamido (-CONH₂), C₁₋₆alkylaminocarbonyl, e.g. methylaminocarbonyl or ethylaminocarbonyl, C₁₋₆dialkylaminocarbonyl, e.g. dimethylaminocarbonyl or diethylaminocarbonyl, phenylaminocarbonyl, sulphonylamino (-NHSO₂H), C₁₋₆alkylsulphonylamino, e.g. methylsulphonylamino or ethylsulphonylamino, C₁₋₆dialkylsulphonylamino, e.g. dimethylsulphonylamino or diethylsulphonylamino, aminosulphonylamino (-NHSO₂NH₂), C₁₋₆alkylaminosulphonylamino, e.g. methylaminosulphonylamino or ethylaminosulphonylamino,

20 C₁₋₆dialkylaminosulphonylamino, e.g. dimethylaminosulphonylamino or diethylaminosulphonylamino, phenylaminosulphonylamino, C₁₋₆alkanoylamino, e.g. acetilamino, C₁₋₆alkanoylaminoC₁₋₆alkyl e.g. acetilaminomethyl or C₁₋₆alkoxycarbonylamino, e.g. methoxycarbonylamino, ethoxycarbonylamino or t-butoxycarbonylamino, thiocarboxamido (-CSNH₂), C₁₋₆alkylaminothiocarbonyl, e.g. methylaminothiocarbonyl or ethylaminothiocarbonyl, C₁₋₆dialkylaminothiocarbonyl, e.g. dimethylaminothiocarbonyl or diethylaminothiocarbonyl, phenylaminothiocarbonyl, aminocarbonylamino, C₁₋₆alkylaminocarbonylamino, e.g. methylaminocarbonylamino or ethylaminocarbonylamino, C₁₋₆dialkylaminocarbonylamino, e.g. dimethylaminocarbonylamino or diethylaminocarbonylamino, aminothiocarbonylamino,

30 C₁₋₆alkylaminothiocarbonylamino, e.g. methylaminothiocarbonylamino or

35

ethylaminothiocarbonylamino, C₁₋₆ dialkylaminothiocarbonylamino, e.g. dimethylaminothiocarbonylamino, or diethylaminothiocarbonylamino, aminocarbonylC₁₋₆alkylamino, e.g. aminocarbonylmethylamino or aminocarbonylethylamino, aminothiocarbonylC₁₋₆alkylamino e.g. aminothiocarbonylmethylamino or aminothiocarbonylethylamino, formylaminoC₁₋₆alkylsulphonylamino, e.g. formylaminomethylsulphonylamino or formylaminoethylsulphonylamino, thioformylaminoC₁₋₆alkylsulphonylamino, e.g. thioformylaminomethylsulphonylamino or thioformylethylsulphonylamino, C₁₋₆acylamino-
sulphonylamino, e.g. acetylamino-
sulphonylamino, e.g. thioacetylamino-
sulphonylamino groups.

Where desired, two R⁹ substituents may be linked together to form a cyclic group such as a cyclic ether, e.g. a C₂₋₆alkylenedioxy group such as ethylenedioxy.

It will be appreciated that where two or more R⁹ substituents are present, these need not necessarily be the same atoms and/or groups. The R⁹ substituents may be present at any ring carbon atom away from that attached to the rest of the molecule of formula (1).

When in the compounds of formula (1) the group Ar is a -(CH₂)_n-Z-Ar' group, the group may be for example an -Ar, -CH₂Ar', -(CH₂)₂-Ar', -(CH₂)₃-Ar', -(CH₂)OAr', -(CH₂)₂OAr', -(CH₂)₃OAr', -CH₂-S-Ar', -(CH₂)₂-S-Ar', -(CH₂)₃-S-Ar', -CH₂-N(R^b)-Ar', -(CH₂)₂-N(R^b)-Ar' or -(CH₂)₃-N(R^b)-Ar' group.

In the compounds of formula (1), when an ester group is present, for example a group CO₂R⁶ or -CO₂Alk³ this may advantageously be a metabolically labile ester.

The presence of certain substituents in the compounds of formula (1) may enable salts of the compounds to be formed. Suitable salts include pharmaceutically acceptable salts, for example acid addition salts derived from inorganic or organic acids, and salts derived from inorganic and organic bases.

Acid addition salts include hydrochlorides, hydrobromides, hydroiodides, alkylsulphonates, e.g. methanesulphonates, ethanesulphonates, or isethionates, arylsulphonates, e.g. p-toluenesulphonates, besylates or napsylates, phosphates, sulphates, hydrogen sulphates, acetates, trifluoroacetates, propionates, citrates, maleates, fumarates, malonates, succinates, lactates, oxalates, tartrates and benzoates.

Salts derived from inorganic or organic bases include alkali metal salts such as sodium or potassium salts, alkaline earth metal salts such as magnesium or calcium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.

Prodrugs of compounds of formula (1) include those compounds, for example esters, alcohols or amines, which are convertible *in vivo* by metabolic means, e.g. by hydrolysis, reduction, oxidation or transesterification, to compounds of formula (1).

Particularly useful salts of compounds according to the invention include pharmaceutically acceptable salts, especially acid addition pharmaceutically acceptable salts.

In the compounds of formula (1) the group =W- is preferably a =C(Y)-group. In compounds of this type Y is preferably a -XR^a group where X is -O- and R^a is an optionally substituted ethyl group or, especially, an optionally substituted methyl group. Especially useful substituents which may be present on R^a groups include one, two or three fluorine or chlorine atoms.

One particularly useful group of compounds of the invention has the formula (1) where L is a group -XR. In compounds of this type X is preferably -O-. The group R in these compounds is preferably an optionally substituted cycloalkyl group, particularly an optionally substituted cyclopentyl group, and is, especially a cyclopentyl group.

In another group of compounds of formula (1) L is preferably a -CH=C(R¹)(R²) group. In compounds of this type R¹ and R² are


preferably linked together with the C atom to which they are attached to form an optionally substituted cycloalkyl or cycloalkenyl group, especially a substituted cyclopentyl or cyclohexyl or, especially, a cyclopentyl or cyclohexyl group.

5

When in compounds of formula (1) Ar' is a substituted pyridyl group it may be for example a mono- or disubstituted pyridyl group, such as a mono- or disubstituted 2-pyridyl, 3-pyridyl or especially 4-pyridyl group substituted by one or two atoms or groups R⁹ as defined above, in particular one or two halogen atoms such as fluorine or chlorine atoms, or methyl, methoxy, hydroxyl or nitro groups. Particularly useful pyridyl groups of these types are 3-monosubstituted-4-pyridyl or 3,5-disubstituted-4-pyridyl, or 2- or 4-monosubstituted-3-pyridyl or 2,4-disubstituted-3-pyridyl groups.

10

15 A particularly useful group of compounds of formula (1) has the formula (2):



where -L is OR, where R is an optionally substituted cycloalkyl group, -CH=C(R¹)(R²) or -CH₂CH(R¹)(R²) group where R¹ and R² are linked together with the carbon atom to which they are attached to form a cycloalkyl group; Ar and R³ are as defined for formula (1); and the salts, solvates, hydrates, prodrugs and N-oxides thereof.

20

25 In general in compounds of formulae (1) and (2) Ar is preferably a -Ar' or -CH₂Ar' group. In compounds of this type, and in general, Ar' is preferably an optionally substituted pyridyl group, particularly as specifically described previously.

25

30 In one particular group of compounds of formulae (1) and (2) the group R³ is preferably a hydrogen atom, or a -CONH₂, or -COR⁷ group, where R⁷ is an optionally substituted alkyl, especially methyl or ethyl, or phenyl group.

30

Particularly useful compounds of formula (1) according to the invention are the (E) and/or (Z) isomers of:

- 1-(3-cyclopentyloxy-4-methoxyphenyl)-2-(2,6-dichloro-4-pyridyl) ethanone oxime;
- 5 0-(aminocarbonyl)-1-(3-cyclopentyloxy-4-methoxy-phenyl)-2-(2,6-dichloro-pyrid-4-yl)ethanone oxime;
- 0-propanoyl-1-(3-cyclopentyloxy-4-methoxy-phenyl)-2-(2,6-dichloropyrid-4-yl)ethanone oxime;
- 10 0-benzoyl-2-(2,6-dichloropyridyl)-1-(3-cyclopentyl-oxy-4-methoxyphenyl)-ethanone oxime;
- 0-methyl-1-(3-cyclopentyloxy-4-methoxyphenyl)-2-[4-(2,6-dichloro-pyridine)]ethanone oxime; and the salts, solvates, hydrates, prodrugs and N-oxides thereof.

- 15 Compounds according to the invention are selective and potent inhibitors of PDE IV. The ability of the compounds to act in this way may be simply determined by the tests described in the Examples hereinafter.

- 20 The compounds according to the invention are thus of particular use in the prophylaxis and treatment of human diseases where an unwanted inflammatory response or muscular spasm (for example bladder or alimentary smooth muscle spasm) is present and where the elevation of cAMP levels may be expected to prevent or alleviate the inflammation and relax muscle.

- 25 Particular uses to which the compounds of the invention may be put include the prophylaxis and treatment of asthma, especially inflamed lung associated with asthma, cystic fibrosis, or in the treatment of inflammatory airway disease, chronic bronchitis, eosinophilic granuloma, psoriasis and
- 30 other benign and malignant proliferative skin diseases, endotoxic shock, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis,
- 35 arterial restenosis and arteriosclerosis.

Compounds of the invention may also suppress neurogenic inflammation through elevation of cAMP in sensory neurones. They are, therefore, analgesic, anti-tussive and anti-hyperalgesic in inflammatory diseases associated with irritation and pain.

5

Compounds according to the invention may also elevate cAMP in lymphocytes and thereby suppress unwanted lymphocyte activation in immune-based diseases such as rheumatoid arthritis, ankylosing spondylitis, transplant rejection and graft versus host disease.

10

Compounds according to the invention may also reduce gastric acid secretion and therefore can be used to treat conditions associated with hypersecretion.

15 Compounds of the invention may suppress cytokine synthesis by inflammatory cells in response to immune or infectious stimulation. They are, therefore, useful in the treatment of bacterial, fungal or viral induced sepsis and septic shock in which cytokines such as tumour necrosis factor (TNF) are key mediators. Also compounds of the invention may suppress
20 inflammation and pyrexia due to cytokines and are, therefore, useful in the treatment of inflammation and cytokine-mediated chronic tissue degeneration which occurs in diseases such as rheumatoid or osteo-arthritis.

25 Over-production of cytokines such as TNF in bacterial, fungal or viral infections or in diseases such as cancer, leads to cachexia and muscle wasting. Compounds of the invention may ameliorate these symptoms with a consequent enhancement of quality of life.

30 Compounds of the invention may also elevate cAMP in certain areas of the brain and thereby counteract depression and memory impairment.

Compounds of the invention may suppress cell proliferation in certain tumour cells and can be used, therefore, to prevent tumour growth and
35 invasion of normal tissues.

For the prophylaxis or treatment of disease the compounds according to the invention may be administered as pharmaceutical compositions, and according to a further aspect of the invention we provide a pharmaceutical composition which comprises a compound of formula (1) together with one
5 or more pharmaceutically acceptable carriers, excipients or diluents.

Pharmaceutical compositions according to the invention may take a form suitable for oral, buccal, parenteral, nasal, topical or rectal administration, or a form suitable for administration by inhalation or insufflation.
10

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets, lozenges or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or
15 hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for
20 oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous
25 vehicles and preservatives. The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.

Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
30

For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

The compounds of formulae (1) and (2) may be formulated for parenteral administration by injection e.g. by bolus injection or infusion. Formulations
35 for injection may be presented in unit dosage form, e.g. in glass ampoule

or multi dose containers, e.g. glass vials. The compositions for injection may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising, preserving and/or dispersing agents.

- 5 Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.

- 10 In addition to the formulations described above, the compounds of formulae (1) and (2) may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation or by intramuscular injection.

- 15 For nasal administration or administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation for pressurised packs or a nebuliser, with the use of suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.


- 20 The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack or dispensing device may be accompanied by instructions for administration.

- 25 The quantity of a compound of the invention required for the prophylaxis or treatment of a particular inflammatory condition will vary depending on the compound chosen, and the condition of the patient to be treated. In general, however, daily dosages may range from around 100ng/kg to 100mg/kg, e.g. around 0.01mg/kg to 40mg/kg body weight for oral or
30 buccal administration, from around 10ng/kg to 50mg/kg body weight for parenteral administration and around 0.05mg to around 1000mg e.g. around 0.5mg to around 1000mg for nasal administration or administration by inhalation or insufflation.

- 35 The compounds according to the invention may be prepared by the following processes. The symbols W, L, L¹, Z, X, R¹, R², R³, R⁴ and R⁵

when used in the formulae below are to be understood to represent those groups described above in relation to formula (1) unless otherwise indicated. In the reactions described below it may be necessary to protect reactive functional groups, for example hydroxy, amino, thio, carboxy or aldehyde groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice [see, for example, Green, T. W. in "Protective Groups in Organic Synthesis" John Wiley and Sons, 1981].

Thus according to a further aspect of the invention, compounds of formula (1) may be prepared by reacting a compound of formula (3)




with a hydroxylamine NH_2OR^3 or a salt thereof.

The reaction may be performed at an elevated temperature, e.g. the reflux temperature and where necessary in the presence of a base, for example, an organic base such as pyridine.


This reaction is particularly suitable for the preparation of compounds of formula (1) where R^3 is a hydrogen atom.

Intermediates of formula (3) may be prepared by oxidation of an alcohol of formula (4)



using an oxidising agent, such as oxalyl chloride $(\text{COCl})_2$ in the presence of dimethylsulphoxide and triethylamine in a solvent, e.g. dichloromethane.


- 5 Intermediates of formula (4) may be prepared by reaction of an aldehyde of formula (5)



- 10 with an organometallic reagent Ar-M [where M is a metal atom, for example a lithium atom] in a solvent such as an ether, e.g. a cyclic ether such as tetrahydrofuran, at a low temperature e.g. around -70°C to ambient temperature.

- 15 Reagents Ar-M are either known compounds or may be prepared, preferably *in situ* during the above process, by reaction of a compound AlkCH_2M or $[\text{Alk}]_2\text{NM}$ [where Alk is an alkyl group such as a n-propyl or i-propyl group] with a compound ArH using the just mentioned reaction conditions.


- 20 Intermediates of formula (5) where L is a $-\text{XR}$ group in which X is $-\text{O}-$, $-\text{S}-$ or $-\text{N}(\text{R}^b)-$ may be prepared by alkylation of an intermediate of formula (6)



- 25 using the reagents and conditions described below for the preparation of a compound of formula (1) from an intermediate of formula (10).

Intermediates of formula (6) are known compounds or may be prepared from known starting materials using similar conditions to those used to prepare the known compounds.

- 5 Intermediates of formula (5) where -W= is -N= may be prepared from an intermediate of formula (7)




- 10 by successive oxidation and reduction reactions.

For example, a first oxidation by SeO_2 or potassium permanganate gives the carboxylic acid derivative. This in turn is reduced by a reducing agent, for example lithium aluminium hydride to give the alcohol, which, upon

15 oxidation with manganese dioxide gives the desired intermediate (5).

Intermediates of formula (7) may be prepared by reacting a halide of formula (8)




20

where Hal is a halogen atom, e.g. a bromine, chlorine or iodine atom with a compound RXH , where X is -O-, -S- or -NH- in the presence of a base.

- 25 Bases used in this reaction include hydrides, such as sodium hydride, or an organometallic base, such as butyllithium in a solvent, such as an amide, for example dimethylformamide at a temperature from room temperature to above, e.g. 80°C .


Intermediates of formula (8) may be prepared by reacting an amine of formula (9)



(9)

5 with nitrous acid (made *in situ* by reacting sodium nitrite with an acid, for example sulphuric acid or hydrobromic acid) to produce the diazonium salt. This in turn may be reacted with a haloacid, e.g. hydrobromic, hydrochloride or hydriodic acid if necessary in the presence of the
10 corresponding copper (I) halide for example CuBr or CuI or halogen, e.g. Br₂, Cl₂ or I₂.

In another process according to the invention, a compound of formula (1) where L is a -XR group in which X is -O-, -S- or -N(R^b)- may be prepared
15 by alkylation of a compound of formula (10):



(10)


using a reagent RL¹, where L¹ is a leaving group.

20 Leaving groups represented by L¹ include halogen atoms such as iodine, chlorine or bromine atoms or sulphonyloxy groups such as arylsulphonyloxy groups, e.g. p-toluenesulphonyloxy.

25 The alkylation reaction may be carried out in the presence of a base, e.g. an inorganic base such as a carbonate, e.g. caesium or potassium carbonate, an alkoxide, e.g. potassium-t-butoxide, or a hydride, e.g. sodium hydride, in a dipolar aprotic solvent such as an amide, e.g. a substituted amide such as dimethylformamide or an ether, e.g. a cyclic -


ether such as tetrahydrofuran, at ambient temperature or above e.g. around 40°C to 50°C.

Intermediates of formula (10) may be obtained from the corresponding
5 protected compound of formula (11):



wherein X¹ is a protected hydroxy, thio or amino group using conventional
10 procedures [see Green, T. W. *ibid*]. Thus, for example, where X is a t-butyl-
dimethylsilyloxy group, the required hydroxyl group may be obtained
by treatment of the protected intermediate with tetrabutylammonium
fluoride. The protected intermediate of formula (11) may be prepared in
an analogous manner to the compounds of formula (1) using the reactions
15 described herein and appropriately protected intermediates.

In a further process according to the invention, compounds of general
formula (1) where L is a $-C(R^5)=C(R^1)(R^2)$ group and R⁵ is a hydrogen
atom or a methyl group, may be prepared by coupling a compound of
20 formula (12)



where R⁵ is as described above with an olefination agent.
25

Particular examples of olefination agents include phosphonium salts such
as compounds $(R^1)(R^2)CHP(D)_3Hal$ where Hal is a halogen atom, such as
a bromine atom, and D is an optionally substituted alkyl, e.g. methyl, or

aryl, especially phenyl, group; phosphoranes $(R^1)(R^2)C=P(D)_3$; phosphonates $(DO)_2P(O)CH(R^1)(R^2)$; or silane derivatives, for example compounds of formula $(D)_3SiC(R^1)(R^2)$, e.g. trialkylsilanes such as $(CH_3)_3SiC(R^1)(R^2)$.

5

Bases for use in the above reaction include organometallic bases, for example, an organolithium compound such as an alkyllithium e.g. n-butyllithium, a hydride, such as sodium or potassium hydride or an alkoxide, such as a sodium alkoxide, e.g. sodium methoxide.

10

The reaction may be performed in a suitable solvent, for example a polar aprotic solvent, such as an alkyl sulphoxide, e.g. methyl sulphoxide, an amide such as N,N-dimethylformamide or hexamethyl-phosphorous triamide; a non-polar solvent, such as an ether, e.g. tetrahydrofuran or diethyl ether or an aromatic solvent such as benzene, toluene or xylene; or a polar protic solvent, such as an alcohol, for example ethanol. Preferably the reaction is carried out at a low temperature, for example from around -78°C to around room temperature.

15

20 The olefination agents used in this reaction are either known compounds or may be prepared from known starting materials using reagents and conditions similar to those used to prepare the known compounds. For example, a phosphorane may be prepared in situ by reaction of a phosphonium salt with a base of the type described above. In another example, a phosphonate may be prepared by reacting a halide $(R^1)(R^2)CHHal$ with a phosphite $(DO)_3P$, as described in the Arbuzov reaction. Silane derivatives may be prepared by reaction of a halosilane $(D)_3SiHal$ with a base, such as lithium diisopropylamide, in a solvent, such as an ether, for example a cyclic ether, e.g. tetrahydrofuran, at low temperature, e.g. -10°C.


25

30

Intermediates of formula (12) where R^5 is a methyl group, may be prepared by reacting an intermediate of formula (12) where R^5 is a hydrogen atom with an organometallic reagent, such as methyllithium or CH_3MgHal , using the conditions just described followed by oxidation of the resulting alcohol, using an oxidising agent, e.g. manganese dioxide.

35


Intermediates of formula (12) where R^5 is a hydrogen atom may be prepared by deprotecting a protected aldehyde of formula (13)



where P is a protected aldehyde group, e.g. a dioxanyl group, using acid hydrolysis e.g. by reaction with trifluoroacetic acid or p-toluene sulphonic acid, in the presence of a solvent, e.g. acetone, or a mixture of solvents, e.g. chloroform and water.

10

Intermediates of formula (13) may be prepared in several steps from the protected intermediates of formula (14)



using similar reagents and conditions described herein above for the preparation of compounds of formula (1) from intermediates of formula (5).

20 According to a further aspect of the invention compounds of formula (1) where L is a group $-C(R^5)=CH(R^1)$ and R^1 is an optionally substituted alkyl, alkenyl or alkynyl group may also be prepared by reaction of an intermediate of formula (12) with an organometallic reagent, followed by dehydration of the resulting alcohol.

25

Examples of organometallic reagents include organolithium R^1Li or organomagnesium R^1MgHal reagents. The reaction with the organometallic reagent may be performed in a solvent such as an ether, such as

diethyl ether or for example a cyclic ether such as tetrahydrofuran, at a low temperature for example -10°C to room temperature. The dehydration may be performed using an acid, for example an organic acid such as p-toluene sulphonic acid or trifluoroacetic acid, in the presence of a base, such as an amine, e.g. triethylamine.

In another aspect of the invention, compounds of general formula (1) where L is a $-\text{C}(\text{R}^5)=\text{C}(\text{R}^1)(\text{R}^2)$ or $[\text{CH}(\text{R}^5)_n]\text{CHR}^1\text{R}^2$ group may be prepared by reacting a compound of formula (10) wherein X is $-\text{O}-$ with (1) a triflate reagent, such as trifluoromethanesulphonic anhydride, to give the aryltriflate derivative; followed by reaction with (2) an organostannane.

The reaction (1) may take place in a solvent, for example a halogenated solvent, such as dichloromethane, or an amine, such as pyridine, or a mixture of solvents, e.g. dichloromethane and pyridine, at a low temperature e.g. around 0°C .

The aryltriflate is then coupled with an organostannane, in the presence of a palladium catalyst and lithium chloride. Examples of organostannane include alkenylstannane, e.g. tri-n-butylethenylstannane, alkylstannane, e.g. tetra-n-butylstannane, or alkynylstannane, e.g. tri-n-butylnylstannane. The palladium catalysts include bis(triphenyl-phosphine)palladium (II) $[\text{Pd}(\text{Cl}_2\text{PPh}_3)_2]$ or tetrakis (triphenylphosphine)palladium (0) $[\text{Pd}(\text{PPh}_3)_4]$. The reaction may take place in a solvent, such as an ether e.g. dioxane or THF or an amide, e.g. DMF, at an elevated temperature, e.g. at reflux.

Compounds of formula (1) may be prepared by interconversion of another compound of formula (1). For example, a compound of formula (1) where L is a $-\text{CH}(\text{R}^5)\text{CHR}^1\text{R}^2$ group may be prepared by hydrogenation of a compound of formula (1) where L is a $\text{C}(\text{R}^5)=\text{C}(\text{R}^1)(\text{R}^2)$ group. The hydrogenation may be performed using for example hydrogen in the presence of a catalyst. Suitable catalysts include metals such as platinum or palladium optionally supported on an inert carrier such as carbon or calcium carbonate; nickel, e.g. Raney nickel, or rhodium. The reaction may be performed in a suitable solvent, for example an alcohol such as methanol or ethanol, an ether such as tetrahydrofuran or dioxane, or an

ester such as ethyl acetate, optionally in the presence of a base, for example a tertiary organic base such as triethylamine, at for example ambient temperature.

- 5 The organostannates are known compounds or may be prepared from known reagents using conditions similar to those used to prepare the known compounds.

- 10 Alternatively, the reaction may be accomplished by transfer hydrogenation using an organic hydrogen donor and a transfer agent. Suitable hydrogen donors include for example acids, such as formic acid, formates, e.g. ammonium formate, alcohols, such as benzyl alcohol or ethylene glycol, hydrazine, and cycloalkenes such as cyclohexene or cyclohexadiene. The transfer agent may be for example a transition metal, for example
15 palladium or platinum, optionally supported on an inert carrier as discussed above, nickel e.g. Raney nickel, ruthenium, e.g. tris (triphenylphosphine) ruthenium chloride or copper. The reaction may generally be performed at an ambient or elevated temperature, optionally in the presence of a solvent, for example an alcohol such as ethanol or an
20 acid such as acetic acid.

- In another interconversion reaction, compounds of formula (1) where R^3 is an alkyl, alkenyl or alkynyl group, e.g. a methyl group, may be prepared by reaction of a compound of formula (1) where R^3 is a hydrogen atom with a
25 diazo compound, such as diazomethane or an alkyl halide e.g. iodomethane or sulphate, if necessary in the presence of a base, such as a hydride, e.g. sodium hydride, and a catalyst, e.g. such as a quaternary ammonium salt, e.g. tetra-n-butylammonium iodide.

- 30 Compounds of formula (1) where R^3 is a $-C(O)NH_2$ group may be prepared by reacting a compound of formula (1), where R^3 is a hydrogen atom, with an isocyanate, such as chlorosulphonyl isocyanate $ClSO_2NCO$, or trichloroacetyl isocyanate $Cl_3C(O)NCO$ (followed by reaction with ammonia) or sodium cyanate $NaOCN$, in a solvent such as a cyclic ether,
35 e.g. tetrahydrofuran or a halogenated solvent, e.g. dichloromethane, if

necessary in the presence of an acid, such as trifluoroacetic acid or acetic acid, at around room temperature.

- 5 Compounds of formula (1) where R^3 is a $-C(O)R^4$ group in which R^4 is an alkylamino or arylamino group may be prepared by reacting a compound of formula (1) where R^3 is a hydrogen atom with an isocyanate $R^4-N=C=O$ (where R^4 is an alkyl or aryl group) in a solvent, e.g. tetrahydrofuran.
- 10 Compounds of formula (1) where R^3 is a $-C(O)R^4$ group in which R^4 is lower alkoxy or aryloxy group, may be prepared by reaction of a compound of formula (1) in which R^3 is a hydrogen atom with a reagent $R^4OC(O)X$ (where R^4 is as just described and X is a leaving group, such as a halogen atom, for example a chlorine atom) in a solvent, e.g.
- 15 dichloromethane.
- 20 Compounds of formula (1) where R^3 is a $-C(O)R^4$ group in which R^4 is an alkyl group, may be prepared by reacting a compound of formula (1) where R^3 is a hydrogen atom with (1) an alkyl anhydride, such as propionic anhydride in a solvent or mixture of solvents such as dichloromethane and pyridine; or (2) with an acid chloride, where necessary in the presence of a base, such as an organic amine, e.g. pyridine.
- 25 In another example of an interconversion, a group represented by Ar^1 or R^4 in compounds of formula (1) may be substituted in the aryl or heteroaryl portions by any of the groups R^9 by an appropriate substitution reaction using the corresponding unsubstituted compound of formula (1) and a R^9 containing nucleophile or electrophile.
- 30 In yet another example of an interconversion process a compound of formula (1) wherein R^3 is a $-C(S)R^4$ group and/or R^4 contains a $-C(S)-$, $-C(S)N$, or $-NC(S)-$ group may be prepared by reacting a compound of formula (1) wherein R^3 is a $-C(O)R^4$ group and/or R^4 contains a $-C(O)-$, $-C(O)N$, or $-NC(O)-$ group with a thiation reagent, such as Lawesson's
- 35 reagent, in an anhydrous solvent, for example toluene, at an elevated temperature, such as the reflux temperature.

In a still further example of interconversion process, a compound of formula (1) wherein R^3 is not a hydrogen atom may be prepared by reacting a compound of formula (1) wherein R^3 is a hydrogen with a diazocompound or an isocyanate R^4NCO , a reagent $R^4OC(O)X$ as described hereinabove for the preparation of a compound of formula (1) from an intermediate of formula (3).

The following examples illustrate the invention. The following abbreviations are used: THF - tetrahydrofuran; Et_2O - diethyl ether; EtOAc - ethyl acetate; LDA - lithium diisopropylamide; RT - room temperature; MeOH - methanol; DMSO - dimethyl sulphoxide; CH_2Cl_2 - dichloromethane; HPLC - high performance liquid chromatography; DMF - dimethylformamide.

INTERMEDIATE 1

3-Cyclopentyloxy-4-methoxybenzaldehyde

The title compound was prepared as described for Intermediate 1 in International Patent Specification No. WO 94/14742.

INTERMEDIATE 2

3,5-Dichloro-4-methylpyridine

The title compound was prepared as described for Intermediate 15 in International Patent Specification No. WO 94/14742.

INTERMEDIATE 3

(±)-4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-hydroxyethyl-3,5-dichloropyridine

The title compound was prepared from Intermediate 2 as described in the compound of Example 1a) in International Patent Specification No. WO 94/20446.

INTERMEDIATE 4

(3-Cyclopentyloxy-4-methoxyphenyl)(3,5-dichloro-4-pyridylmethyl) ketone

A solution of DMSO (2.77g, 35.5mmol) in CH₂Cl₂ (15ml) was added to a solution of oxalyl chloride (2.08g, 16.4mmol) in CH₂Cl₂ (40ml) at ca. -70°C. After stirring at -20°C for 0.25h, a solution of Intermediate 3 (5.65g, 14.8mmol) in CH₂Cl₂ (90ml) was added over 0.25h and the reaction mixture maintained at <-50°C for 0.5h. Triethylamine (6.95g, 68.7mmol) was then added and the mixture allowed to warm to RT. The reaction mixture was quenched with water (75ml) and extracted with CH₂Cl₂ (2x75ml). The extract was washed with saturated sodium bicarbonate solution (30ml), then brine (30ml), dried (MgSO₄), and concentrated in vacuo. The residue was subjected to chromatography (SiO₂; 1% MeOH-CH₂Cl₂) to afford the title compound (4.94g) as an off-white solid m.p. 129-130°C; δ_H (CDCl₃) 1.5-2.1 (8H, br m, CH₂)₄), 3.95 (3H, s, OMe), 4.64 (2H, s, COCH₂), 4.85 (1H, br m, OCH), 6.94 (1H, d, J 8.4Hz, ArH ortho to OMe), 7.57 (1H, d, J 2.0Hz, ArH ortho to cyclopentyloxy), 7.69 (1H, dd, J 8.4, 2.0Hz, ArH para to cyclopentyloxy), and 8.51 (2H, s, pyridine H₂, H₆).

EXAMPLE 1

(E) and (Z) Isomers of 1-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(2,6-dichloropyrid-4-yl)ethanone oxime

A mixture of Intermediate 4 (2.5g, 6.6mmol) and hydroxylamine hydrochloride (0.55g, 7.9mmol) in pyridine (15ml) was heated to reflux for 3 days. The solvent was removed in vacuo and the residue partitioned between EtOAc (40ml) and saturated NaHCO₃ solution (30ml). The organic layer was separated, then dried (MgSO₄), and concentrated in vacuo. The residual brown oil was triturated with Et₂O (20ml) to afford the title compound (single isomer -(E)- or (Z)- isomer; unassigned) (1.2g) as a white solid m.p. 139-140°C (Found: C, 57.60; H, 4.97; N, 6.83 C₁₉H₂₀Cl₂N₂O₃. requires C, 57.73; H, 5.10; N, 7.09%); δ_H (CDCl₃) 1.5-2.0 (8H, br m, (CH₂)₄), 3.81 (3H, s, OMe), 4.44 (2H, s, CH₂ pyridine), 4.70 (1H, br m, OCH), 6.74 (1H, d, J 8.4Hz, ArH ortho to OMe), 6.95 (1H, d, J 2.0Hz, ArH ortho to cyclopentyloxy), 6.97 (1H, dd, J 8.4, 2.0Hz, ArH para to cyclopentyloxy), 8.38 (2H, s, pyridine H₂, H₆), and 8.52 (1H, br s, NOH).

The ether soluble portion was concentrated in vacuo and triturated with hexane (20ml) to afford (E)- and (Z)- title compound (0.53g) as a white

solid m.p. 129-130°C (¹Hnmr indicates 1:1 mixture ; δ_{OMe} 3.81 and 3.90, δ_{CH₂} 4.15 and 4.44, δ_{OCH} 4.70 and 4.80, δ_{pyridine H₂, H₆} 8.38 and 8.48).

EXAMPLE 2

5 (E) and (Z) isomers of O-(Aminocarbonyl)-1-(3-cyclopentyloxy-4-methoxyphenyl)-2-(2,6-dichloropyrid-4-yl)ethanone oxime

To a slowly stirred suspension of sodium cyanate (0.67g, 10.29mmol) in CH₂Cl₂ (5ml) was added anhydrous trifluoroacetic acid (0.587g, 0.395ml, 4.0mmol) dropwise over 5 min at RT. The suspension was slowly stirred and mechanically agitated over a period of 2h at RT, affording a gelatinous mass. A solution of the compound of Example 1 (1:1 mixture of E and Z isomers) (0.507g, 1.3mmol) in CH₂Cl₂ (2ml) was added in one portion. The reaction mixture was stirred and agitated over 2 days then poured into saturated NaHCO₃ solution (25ml) and extracted with CH₂Cl₂ (3x20ml). The combined organic extract was washed with water (10ml), dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by chromatography (SiO₂; EtOAc/hexane (1:1)) affording the title compound (178mg) as a mixture of E and Z isomers. Separation by HPLC (C₁₈ column, CH₃CN/H₂O(1:1) eluant, 10ml. min⁻¹ flow rate) afforded both isomers in pure form:

Minor isomer (64mg) as a white foam, (stereochemistry unassigned; elution time = 21 min); (Found: C, 54.55; H, 4.79; N, 9.36. C₂₀H₂₁Cl₂N₃O₄ requires C, 54.81; H, 4.83; N, 9.59%); δ_H (CDCl₃) 1.5-2.0 (8H, br m, (CH₂)₄), 3.80 (3H, s, OMe), 4.56 (2H, s, CH₂ pyridine), 4.65 (1H, br m, OCH), 5.15 (1H, br s, NH), 6.30 (1H, br s, NH), 6.74 (1H, d, J 8Hz, ArH ortho to OMe), 6.90 (1H, d, J 2Hz, ArH ortho to cyclopentyloxy), 7.02 (1H, dd, J 8, 2Hz, ArH para to cyclopentyloxy), 8.45 (2H, s, pyridine H₂, H₆).

Major isomer (79mg) as a white foam (stereochemistry unassigned; elution time = 26min); (Found: C, 54.61; H, 4.83; N, 9.53. C₂₀H₂₁Cl₂N₃O₄ requires C, 54.81; H, 4.83; N, 9.59%); δ_H (CDCl₃) 1.5-2.0 (8H, br m, (CH₂)₄), 3.88 (3H, s, OMe), 4.37 (2H, s, CH₂ pyridine), 4.78 (1H, br m, OCH), 5.0 (1H, br s, NH), 5.70 (1H, br s, NH), 6.89 (1H, d, J 8Hz, ArH ortho to OMe), 7.13 (1H, d, J 2Hz, ArH ortho to cyclopentyloxy), 7.17 (1H, dd, J 8, 2Hz, ArH para to cyclopentyloxy), 8.68 (1H, br s, pyridine H₂, H₆).

EXAMPLE 3**O-Propanoyl-1-(3-cyclopentyloxy-4-methoxyphenyl)-2-(2,6-dichloro-pyrid-4-yl)ethanone oxime**

- 5 To a stirred, ice-bath cooled solution of the compound of Example 1 (0.5g, 1.27mmol; single isomer; stereochemistry unassigned) in CH₂Cl₂/pyridine (10:1, 5ml) was added dropwise propionic anhydride (0.182g, 0.18ml, 1.4mmol) under a nitrogen atmosphere. The reaction mixture was stirred briefly at this temperature then allowed to warm to RT. The solvent was
- 10 removed *in vacuo* and the crude product azeotroped several times with toluene (3x30ml). The obtained brown oil was subjected to chromatography (SiO₂, EtOAc/Hexane (1:3)) affording the title compound (0.512g) as a white waxy solid m.p. 92-93°C. (Found: C, 58.50; H, 5.35; N, 6.21. C₂₂H₂₄Cl₂N₂O₄ requires C, 58.54; H, 5.36; N, 6.21%); δ_H
- 15 (CDCl₃) 1.20 (3H, t, \downarrow 7.5Hz, CH₃CH₂), 1.5-2.0 (8H, br m, (CH₂)₄), 2.41 (2H, q, \downarrow 7.5Hz, CH₂CH₃), 3.82 (3H, s, OMe), 4.46 (2H, s, CH₂ pyridine), 4.73 (1H, br m, OCH), 6.76 (1H, d, \downarrow 8.5Hz, ArH ortho to OMe), 7.08 (1H, d, \downarrow 2Hz, ArH ortho to cyclopentyloxy), 7.16 (1H, dd, \downarrow 8.5, 2Hz, ArH para to cyclopentyloxy), 8.40 (1H, s, pyridine H₂, H₆).
- 20

EXAMPLE 4**(E) and (Z) isomers of O-(Phenylcarbonyl)-1-(3-cyclopentyloxy-4-methoxyphenyl)-2-(2,6-dichloropyrid-4-yl)ethanone oxime**

- The compound of Example 1 (0.7g) in dry CH₂Cl₂ (20ml) was stirred and
- 25 cooled in an ice-bath before adding pyridine (0.29ml) and benzoyl chloride (0.25ml). The reaction was stirred for 5min under nitrogen then left to warm to RT and stir for another 4h. The reaction mixture was partitioned between CH₂Cl₂ (100ml) and saturated aqueous NaHCO₃ (100ml), the phases were separated and the aqueous phase extracted with CH₂Cl₂
- 30 (2x50ml). The combined organic phase was washed with brine (25ml), dried (MgSO₄) and concentrated *in vacuo* to afford a colourless oil. Upon cooling and trituration with hexane, the title compound (0.71g) was obtained as an off-white powder m.p. 109-111°C. (Found C, 62.50; H, 4.85; N, 5.42. C₂₆H₂₄Cl₂N₂O₄ requires C, 62.53; H, 4.84; N, 5.61).
- 35 δ_H (CDCl₃) 1.5-2.0 (8H, br m, (CH₂)₄), 3.81(3H, s, OMe), 4.61 (2H, s, pyridine), 4.73 (1H, br s OCH), 6.77 (1H, d, \downarrow 8.5Hz, ArH ortho to

methoxy), 7.10 (1H, d, Δ 2.2Hz, ArH ortho to cyclopentyloxy), 7.18 (1H, dd, Δ 8.5, 2.2Hz, ArH para to cyclopentyloxy), 7.44-7.49 (2H, m, 2 x Ph-H), 7.58-7.63 (1H, m, 1 x Ph-H), 8.01 (1H, app.d, Δ 6Hz, 2 x Ph-H); 8.37 (2H, s, 2 x pyridine H).

5

EXAMPLE 5

(E) and (Z) isomers of 0-Methyl-1-(3-cyclopentyloxy-4-methoxy-phenyl)-2-[4-(2,6-dichloropyridine)]ethane oxime.

The compound of Example 1 (1.0g) was added to a stirred suspension of NaH (0.132g) (60% dispersion in mineral oil) in dry THF (25ml) at RT under nitrogen. After 1h a few crystals of tetra n-butylammonium iodide were added and the reaction stirred at RT until no more H₂ evolved (about 30min). The pale yellow solution was cooled with an ice-bath before adding iodomethane. The reaction mixture was stirred for 15min at 0°C, then 5hr at RT, quenched with aqueous NH₄Cl and partitioned between 10% aqueous NH₄Cl (25ml) and Et₂O (70ml). The combined organic phase was washed with brine (10ml), dried (MgSO₄) and concentrated *in vacuo*. The residual dark oil was purified by chromatography (SiO₂; CH₂Cl₂) to afford the title compound (160mg), as a mixture of 60% free base and 40% HCl salt, as a colourless oil. (Found: C, 56.72; H, 5.38; N, 6.72. C₂₀H₂₂N₂O₃Cl₂ (60% free base, 40% HCl salt) requires C, 56.77; H, 5.33; N, 6.62%). δ_H (CDCl₃) 1.5-2.0 (8H, br m, (CH₂)₄), 3.80 (3H, s, ArOMe), 3.95 (3H, s, NOMe), 4.38 (2H, s, CH₂ pyridine), 4.70 (1H, br m, OCH), 6.73 ((1H, d, Δ 8.2Hz, ArH ortho to methoxy), 6.97-7.01 (2H, m, 2 x ArH), 8.39 (2H, s, 2 x pyridine H).

The activity and selectivity of compounds according to the invention was demonstrated in the following tests. In these tests the abbreviation FMLP represents the peptide N-formyl-met-leu-phe.

30

1. Isolated Enzyme

The potency and selectivity of the compounds of the invention was determined using distinct PDE isoenzymes as follows:

35

- i. PDE I, rabbit heart
- ii. PDE II, rabbit heart

- iii. PDE III, rabbit heart, Jurkat cells
- iv. PDE IV, HL60 cells, rabbit brain, rabbit kidney and human recombinant PDE IV
- v. PDE V, rabbit lung, guinea pig lung

5

A gene encoding human PDE IV has been cloned from human monocytes (*Livi, et al., 1990, Molecular and Cellular Biology, 10, 2678*). Using similar procedures we have cloned human PDE IV genes from a number of sources including eosinophils, neutrophils, lymphocytes, monocytes, brain and neuronal tissues. These genes have been transfected into yeast using an inducible vector and various recombinant proteins have been expressed which have the biochemical characteristics of PDE IV (*Beavo and Reifsnyder, 1990, TIPS, 11, 150*). These recombinant enzymes, particularly the human eosinophil recombinant PDE IV, have been used as the basis of a screen for potent, selective PDE IV inhibitors.

10
15

The enzymes were purified to isoenzyme homogeneity using standard chromatographic techniques.

20

Phosphodiesterase activity was assayed as follows. The reaction was conducted in 150µl of standard mixture containing (final concentrations): 50mM 2-[[tris(hydroxymethyl)methyl]amino]-1-ethanesulphonic acid (TES) -NaOH buffer (pH 7.5), 10mM MgCl₂, 0.1µM [³H]-cAMP and vehicle or various concentrations of the test compounds. The reaction was initiated by addition of enzyme and conducted at 30°C for between 5 to 30 min. The reaction was terminated by addition of 50µl 2% trifluoroacetic acid containing [¹⁴C]-5'AMP for determining recovery of the product. An aliquot of the sample was then applied to a column of neutral alumina and the [³H]-cAMP eluted with 10ml 0.1 TES-NaOH buffer (pH8). The [³H]-5'-AMP product was eluted with 2ml 2M NaOH into a scintillation vial containing 10ml of scintillation cocktail. Recovery of [³H]-5'AMP was determined using the [¹⁴C]-5'AMP and all assays were conducted in the linear range of the reaction.

25
30
35

Compounds according to the invention cause a concentration-dependent inhibition of recombinant PDE IV at 0.1 - 1000nM with little or no activity against PDE I, II, III or V at concentrations up to 100µM.

5 2. **The Elevation of cAMP in Leukocytes**

10 The effect of compounds of the invention on intracellular cAMP was investigated using human neutrophils or guinea pig eosinophils. Human neutrophils were separated from peripheral blood, incubated with dihydrocytochalasin B and the test compound for 10 min and then stimulated with FMLP. Guinea pig eosinophils were harvested by peritoneal lavage of animals previously treated with intra-peritoneal injections of human serum. Eosinophils were separated from the peritoneal exudate and incubated with isoprenaline and test compound. With both cell types, suspensions were centrifuged at the end of the incubation, the cell pellets were resuspended in buffer and boiled for 10 min prior to measurement of cAMP by specific radioimmunoassay (DuPont).

15 3. **Suppression of Leukocyte Function**

20 Compounds of the invention were investigated for their effects on superoxide generation, chemotaxis and adhesion of neutrophils and eosinophils. Isolated leukocytes were incubated with dihydrocytochalasin B for superoxide generation only and test compound prior to stimulation with FMLP. The most potent compounds of the Examples caused a concentration-dependent inhibition of superoxide generation, chemotaxis and adhesion at concentrations of 0.1nM to 1µM.


25 Lipopolysaccharide (LPS)-induced synthesis of tumour necrosis factor (TNF) by human peripheral blood monocytes (PBM) is inhibited by compounds of the invention at concentrations of 0.01nM to 10µM.

30 4. **Adverse Effects**

35 In general, in our tests, compounds of the invention have had no observed toxic effects when administered to animals at pharmacologically effective doses.

CLAIMS

1. A compound of formula (1)



wherein

=W- is (1) =C(Y)- where Y is a halogen atom, or an alkyl or -XR^a group where X is -O-, -S(O)_m- [where m is zero or an integer of value 1 or 2], or -N(R^b)- [where R^b is a hydrogen atom or an optionally substituted alkyl group] and R^a is a hydrogen atom or an optionally substituted alkyl group or, (2) =N-;


L is a -XR, [where R is an optionally substituted alkyl, alkenyl, cycloalkyl or cycloalkenyl group], -C(R⁵)=C(R¹)(R²) or [-CH(R⁵)]_nCH(R¹)(R²) group where R⁵ is a hydrogen or a fluorine atom or a methyl group, and R¹ and R², which may be the same or different, is each a hydrogen or fluorine atom or an optionally substituted alkyl, alkenyl, alkynyl, alkoxy, alkylthio, -CO₂R⁶, [where R⁶ is a hydrogen atom or an optionally substituted alkyl, aralkyl, or aryl group], -CONR⁷R⁸ [where R⁷ and R⁸, which may be the same or different are as defined for R⁶], -CSNR⁷R⁸, -CN or -NO₂ group, or R¹ and R² together with the C atom to which they are attached are linked to form an optionally substituted cycloalkyl or cycloalkenyl group and n is zero or the integer 1;

Ar is a group -(CH₂)_n-Z-Ar' where Ar' is an optionally substituted monocyclic or bicyclic heteroaryl group and Z is a bond, an atom -O-, or -S- or a group -N(R^b)- and n is zero or the integer 1, 2, 3 or 4;

R³ is a hydrogen atom, or an optionally substituted alkyl, alkenyl, alkynyl, -C(O)R⁴ (where R⁴ is an amino, alkylamino, arylamino, alkoxy, aryloxy or an optionally substituted alkyl group) or -C(S)R⁴ group;

and the salts, solvates, hydrates, prodrugs and N-oxides thereof.


2. A compound according to Claim 1 wherein =W- is =C(Y)- in which Y is a -XR^a group, and L is a -XR group.
3. A compound according to Claim 2 wherein -X- is -O-, R^a is a C₁₋₃ alkyl group and R is an optionally substituted cyclopentyl group.
4. A compound according to Claims 1 to 3 wherein Ar is a group -CH₂-Ar'.
5. A compound according to Claim 4 wherein Ar' is an optionally substituted pyridyl group.
6. A compound according to any of the previous claims wherein R³ is a hydrogen atom or a -CONH₂, or -COR⁷ group where R⁷ is an optionally substituted alkyl or phenyl group.
7. A compound which is the (E) and/or (Z) isomer of:
1-(3-cyclopentyloxy-4-methoxyphenyl)-2-(2,6-dichloro-4-pyridyl)ethanone oxime;
0-(aminocarbonyl)-1-(3-cyclopentyloxy-4-methoxy-phenyl)-2-(2,6-dichloro-pyrid-4-yl)ethanone oxime;
0-propanoyl-1-(3-cyclopentyloxy-4-methoxy-phenyl)-2-(2,6-dichloropyrid-4-yl)ethanone oxime;
0-benzoyl-2-(2,6-dichloropyridyl)-1-(3-cyclopentyl-oxy-4-methoxy-phenyl)-ethanone oxime;
0-methyl-1-(3-cyclopentyloxy-4-methoxyphenyl)-2-[4-(2,6-dichloro-pyridine)]ethanone oxime;
and the salts, solvates, hydrates, prodrugs and N-oxides thereof.
8. A pharmaceutical composition which comprises a compound of formula (1)



wherein

- 5 =W- is (1) =C(Y)- where Y is a halogen atom, or an alkyl or -XR^a group where X is -O-, -S(O)_m- [where m is zero or an integer of value 1 or 2], or -N(R^b)- [where R^b is a hydrogen atom or an optionally substituted alkyl group] and R^a is a hydrogen atom or an optionally substituted alkyl group or, (2) =N-;
- 10 L is a -XR, [where R is an optionally substituted alkyl, alkenyl, cycloalkyl or cyloalkenyl group], -C(R⁵)=C(R¹)(R²) or [-CH(R⁵)]_nCH(R¹)(R²) group where R⁵ is a hydrogen or a fluorine atom or a methyl group, and R¹ and R², which may be the same or different, is each a hydrogen or fluorine atom or an optionally substituted alkyl, alkenyl, alkynyl, alkoxy, alkylthio, -CO₂R⁶, [where
- 15 R⁶ is a hydrogen atom or an optionally substituted alkyl, aralkyl, or aryl group], -CONR⁷R⁸ [where R⁷ and R⁸, which may be the same or different are as defined for R⁶], -CSNR⁷R⁸, -CN or -NO₂ group, or R¹ and R² together with the C atom to which they are attached are linked to form an optionally substituted cycloalkyl or cycloalkenyl
- 20 group and n is zero or the integer 1;
- Ar is a group -(CH₂)_n-Z-Ar' where Ar' is an optionally substituted monocyclic or bicyclic heteroaryl group and Z is a bond, an atom -O-, or -S- or a group -N(R^b)- and n is zero or the integer 1, 2, 3 or 4;
- 25 R³ is a hydrogen atom, or an optionally substituted alkyl, alkenyl, alkynyl, -C(O)R⁴ (where R⁴ is an amino, alkylamino, arylamino, alkoxy, aryloxy or an optionally substituted alkyl group) or -C(S)R⁴ group; and the salts, solvates, hydrates, prodrugs and N-oxides thereof;
- 30 together with one or more pharmaceutically acceptable carriers, excipients or diluents.

9. A process for the preparation of a compound of formula (1)




wherein

- 5 =W- is (1) =C(Y)- where Y is a halogen atom, or an alkyl or -XR^a group where X is -O-, -S(O)_m- [where m is zero or an integer of value 1 or 2], or -N(R^b)- [where R^b is a hydrogen atom or an optionally substituted alkyl group] and R^a is a hydrogen atom or an optionally substituted alkyl group or, (2) =N-;
- 10 L is a -XR, [where R is an optionally substituted alkyl, alkenyl, cycloalkyl or cycloalkenyl group], -C(R⁵)=C(R¹)(R²) or [-CH(R⁵)]_nCH(R¹)(R²) group where R⁵ is a hydrogen or a fluorine atom or a methyl group, and R¹ and R², which may be the same or different, is each a hydrogen or fluorine atom or an optionally substituted alkyl, alkenyl, alkynyl, alkoxy, alkylthio, -CO₂R⁶, [where
- 15 R⁶ is a hydrogen atom or an optionally substituted alkyl, aralkyl, or aryl group], -CONR⁷R⁸ [where R⁷ and R⁸, which may be the same or different are as defined for R⁶], -CSNR⁷R⁸, -CN or -NO₂ group, or R¹ and R² together with the C atom to which they are attached are linked to form an optionally substituted cycloalkyl or cycloalkenyl group and n is zero or the integer 1;
- 20 Ar is a group -(CH₂)_n-Z-Ar' where Ar' is an optionally substituted monocyclic or bicyclic heteroaryl group and Z is a bond, an atom -O-, or -S- or a group -N(R^b)- and n is zero or the integer 1, 2, 3 or 4;
- 25 R³ is a hydrogen atom, or an optionally substituted alkyl, alkenyl, alkynyl, -C(O)R⁴ (where R⁴ is an amino, alkylamino, arylamino, alkoxy, aryloxy or an optionally substituted alkyl group) or -C(S)R⁴ group; and the salts, solvates, hydrates, prodrugs and N-oxides thereof;
- 30 which comprises in a final step.


- a) reacting a compound of formula (3)

39




with a hydroxylamine NH_2OR^3 or a salt thereof;

- 5 b) alkylating an intermediate of formula (10)



- 10 where X is -O-, -S- or -N(R^b)-
with a reagent RL^1 , where L^1 is a leaving group;


- c) coupling a compound of formula (12)



- 15 where R^5 is a hydrogen atom or a methyl group with an olefination agent to yield a compound of formula (1) where L is a $-\text{C}(\text{R}^5)=\text{C}(\text{R}^1)(\text{R}^2)$ group and R^5 is as just defined;


- 20 d) reacting a compound of formula (12)

40



where R^5 is a hydrogen atom or a methyl group with an organometallic reagent followed by dehydration of the resulting alcohol to give a compound of formula (1) where L is a group $-C(R^5)=CH(R^1)$ in which R^1 is an optionally substituted alkyl, alkenyl or alkynyl group and R^5 is as just defined;

e) reacting a compound of formula (10)



wherein-X- is -O-

with (1) a triflate reagent followed by (2) an organostannate to give a compound of formula (1) wherein L is a $-C(R^5)=C(R^1)(R^2)$ or $-[CH(R^5)]_nCHR^1R^2$ group;

or

f) interconverting a compound of formula (1) to another compound of formula (1).

INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/GB 95/01474

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D213/53 A61K31/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,94 10118 (CELLTECH LIMITED) 11 May 1994 see the whole document ---	1-9
X	JOURNAL OF MEDICINAL CHEMISTRY, vol.19, no.2, 1976, WASHINGTON US pages 202 - 208 L.J. FLIEDNER ET AL. 'Synthesis and evaluation of 1,omega-diaryl-1,omega-alkanediamines related to the fibrinolytic bis(tetrahydroisoquinolines) and bis(benzylamines).' see compounds 23 and 29 --- -/--	1,2,6

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

26 September 1995

Date of mailing of the international search report

05.10.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Bosma, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 95/01474

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	TRENDS IN PHARMACOLOGICAL SCIENCES, vol.11, 1990, CAMBRIDGE GB pages 150 - 155 J.A. BEAVO ET AL. 'Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors.' cited in the application see the whole document ---	1,9
A	TRENDS IN PHARMACOLOGICAL SCIENCES, vol.12, 1991, CAMBRIDGE GB pages 19 - 27 C.D NICHOLSON ET AL. 'Different modulation of tissue function and therapeutic optential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes.' cited in the application see the whole document -----	1,9

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
The subject matter of the present claims 1-4,6,8,9 is so broad that a complete search is not possible on economic grounds (PCT Search Guidelines III 3.6 and 3.7). Therefore the search has been based on the examples and the claims as indicated. (Claims searched incompletely 1-4,6,8,9)
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9410118	11-05-94	AU-B- 5340894	24-05-94
		CA-A- 2126072	11-05-94
		EP-A- 0618889	12-10-94
		JP-T- 7502762	23-03-95